Free Access
Issue
Méd. Intensive Réa.
Volume 26, Number 3, Mai 2017
Infectieux
Page(s) 233 - 241
Section Mise au point / Update
DOI https://doi.org/10.1007/s13546-017-1281-4
Published online 04 May 2017
  • Tygacil. Résumé des Caractéristiques Produit. Vidal 2016 [Google Scholar]
  • EUCAST Clinical breakpoints. www.eucast.org/clinical_breakpoints/ [Google Scholar]
  • http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFMV1_0_MARS_2017.pdf [Google Scholar]
  • Pournaras S, Koumaki V, Spanakis N, Gennimata V, Tsakris A, (2016) Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. Int J Antimicrob Agents 48: 11–8 [CrossRef] [PubMed] [Google Scholar]
  • Frampton JE, Curran MP, (2005) Tigécycline. Drugs 65: 2623–2635 [PubMed] [Google Scholar]
  • McGowan AP, (2008) Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 62(Suppl 1): i11–i16 [PubMed] [Google Scholar]
  • Xie J, Wang T, Sun J, Chen S, Cai J, Zhang W, Dong H, Hu S, Zhang D, Wang X, Dong Y, (2014) Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Int J Infect Dis 18: 62–67 [CrossRef] [PubMed] [Google Scholar]
  • Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, Korth-Bradley J, Ambrose PG, (2012) Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 56: 1065–1072 [CrossRef] [PubMed] [Google Scholar]
  • McGovern PC, Wible M, Korth-Bradley JM, Quintana A, (2014) Pancreatitis in tigecycline Phase 3 and 4 clinical studies. J Antimicrob Chemother 69: 773–778 [PubMed] [Google Scholar]
  • Davido B, Shourick J, Makhloufi S, Dinh A, Salomon J, (2016) True incidence of tigecycline-induced pancreatitis: how many cases are we missing? J Antimicrob Chemother 71: 2994–2995 [PubMed] [Google Scholar]
  • Okon E, Engell C, van Manen R, Brown J, (2013) Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. Pharmacotherapy 33: 63–68 [PubMed] [Google Scholar]
  • Tärnberg M, Nilsson LE, Dowzicky MJ, (2016) Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010–2014. Int J Infect Dis 49: 141–148 [CrossRef] [PubMed] [Google Scholar]
  • Rodloff AC Dowzicky MJ, (2017) Antimicrobial susceptibility among european gram-negative and gram-positive isolates collected as part of the tigecycline evaluation and surveillance trial (2004-2014). Chemotherapy 62: 1–11 [PubMed] [Google Scholar]
  • Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN, (2015) Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Int J Antimicrob Agents 46: 725–727 [CrossRef] [PubMed] [Google Scholar]
  • Froment Gomis P, Jean-Pierre H, Rousseau-Didelot MN, Compan B, Michon AL, Godreuil S, (2013) Tigecycline: CMI 50/90 towards 1766 Gram-negative bacilli (3rd generation cephalosporins resistant Enterobacteriaceae), Acinetobacter baumannii and Bacteroides fragilis group, University Hospital - Montpellier, 2008-2011. Pathol Biol (Paris) 61: 282–285 [CrossRef] [PubMed] [Google Scholar]
  • Bris C, Auger G, Kowalczyk F, Eveillard M, Joly-Guillou ML, Kempf M, (2012) In vitro activity of tigecycline on 760 bacterial strains isolated in the hospital university of Angers -2006-2009 TEST study. Path Biol (Paris) 60: 336–339 [CrossRef] [Google Scholar]
  • Cattoir V, Dowzicky MJ, (2014) A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012. Antimicrob Resist Infect Control 3: 36 [CrossRef] [PubMed] [Google Scholar]
  • Montravers P, Dupont H, Bedos JP, Bret P, (2014) The Tigecycline Group. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med 40: 988–997 [CrossRef] [PubMed] [Google Scholar]
  • Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, 311 Study Group, (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68: 140–151 [Google Scholar]
  • Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC, (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57: 1756–1762 [CrossRef] [PubMed] [Google Scholar]
  • van Duin D, Cober ED, Richter SS, Perez F, Cline MKaye KS, Kalayjian RC, Salata RA, Evans SR, Fowler VGJr, Bonomo RA, (2014) Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 20: O1117–20 [PubMed] [Google Scholar]
  • Cunha BA, (2015) Tigecycline dosing is critical in preventing tigecycline resistance because relative resistance is, in part, concentration dependent. Clin Microbiol Infect 21: e39–e40 [PubMed] [Google Scholar]
  • FDA drug safety communication: increased risk of death with Tygacil (Tigecycline) compared to other antibiotics used to treat similar infections. 2010. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm [Google Scholar]
  • Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E, (2008) Clinical and microbiological outcomes of serious infections with multidrug-resistant gam-negative organisms treated with tigecycline. Clin Infect Dis 46: 567–570 [CrossRef] [PubMed] [Google Scholar]
  • Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME, (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895–904 [PubMed] [Google Scholar]
  • Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, Hoppe-Hoppe Tichy T, Markus Büchler, Markus A. Weigand MA, (2008) Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61: 729–733 [PubMed] [Google Scholar]
  • Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo AR, Shrestha NK, Fraser TG, van Duin D, (2011) Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diag Microbiol Infect Dis 69: 357–362 [CrossRef] [Google Scholar]
  • Yahav D, Lador A, Paul M, Leibovici L, (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66: 1963–1971 [PubMed] [Google Scholar]
  • Cai Y, Wang R, Liang B, Bai N, Liu Y, (2011) Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55: 1162–1172 [CrossRef] [PubMed] [Google Scholar]
  • Prasad P, Sun J, Danner RL, Natanson C, (2012) Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54: 1699–1709 [CrossRef] [PubMed] [Google Scholar]
  • Tasina E, Haidich AB, Kokkali S, Arvanitidou M, (2011) Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11: 834–844 [CrossRef] [PubMed] [Google Scholar]
  • McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD, (2013) All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 41: 463–467 [CrossRef] [PubMed] [Google Scholar]
  • www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000644/WC500044509.pdf [Google Scholar]
  • Entenza JM, Moreillon P, (2009) Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Intern J Antimicrob Agents 34: 8e1–8e9 [CrossRef] [Google Scholar]
  • Bassetti M, Peghin M, Davide Pecori D, (2016) The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis 29: 583–594 [CrossRef] [PubMed] [Google Scholar]
  • Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Aggeliki Poulou A, Tsakris A, (2011) Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Intern J Antimicrob Agents 37: 244–247 [CrossRef] [Google Scholar]
  • Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group, (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl 5): S354–S367 [CrossRef] [PubMed] [Google Scholar]
  • Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E, 300 cSSSI Study Group Tigecycline 305 cSSSI Study Group, (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl 5): S341–S353 [CrossRef] [PubMed] [Google Scholar]
  • Bassetti M, McGovern PC, Wenisch C, Meyer RD, Li Yan J, Wible M, Rottinghaus ST, Quintana A, (2015) Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials. Intern J Antimicrob Agents 46: 346–350 [CrossRef] [Google Scholar]
  • Eckmann C, Montravers P, Bassetti M, Bodmann KF, Heizmann WR, Sánchez García M, Guirao X, Capparella MR, Simoneau D, Dupont H, (2013) Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 68(Suppl 2): ii25–35 [CrossRef] [PubMed] [Google Scholar]
  • Solomkin J, Mullins CD, Quintana, Eckmann AC, Shelbaya A, Ernst FR, Krukas MR, and Reisman A, (2016) Evaluation of tigecycline efficacy and post-discharge outcomes in a clinical practice population with complicated intra-abdominal infection: a propensity score-matched analysis. Surg Infect 17: 402–411 [CrossRef] [Google Scholar]
  • Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC, (2014) Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infectious Diseases 14: 102 [CrossRef] [PubMed] [Google Scholar]
  • Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD, (2013) Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis 45: 315–319 [CrossRef] [PubMed] [Google Scholar]
  • van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, Evans S, Fowler VG, Kaye KS, Bonomo RA, (2015) Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70: 1203–1211 [PubMed] [Google Scholar]
  • Xu L, Wang YL, Du S, Chen L, Long LH, Wu Y, (2016) Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy 61: 323–330 [PubMed] [Google Scholar]
  • Chaari A, Pham T, Mnif B, Chtara K, Medhioub F, Baccouche N, Bahloul L, Hammani A, Bouaziz M, (2015) Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study. Intensive Care Med 41: 2018–2019 [CrossRef] [PubMed] [Google Scholar]
  • Tsala M, Vourli S, Daikos GL, Tsakris A, Zerva L, Mouton JW, Meletiadis J, (2017) Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. J Antimicrob Chemother 72: 172–180 [PubMed] [Google Scholar]
  • Montravers P, Bassetti M, Dupont H, Eckmann C, Heizmann WR, Guirao X, García MS, Capparella MR, Simoneau D, Bodmann KF, (2013) Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 68(Suppl 2): ii15–24 [PubMed] [Google Scholar]
  • Montravers P, Dupont H, Leone M, Constantin JM, Mertes PM; Société française d’anesthésie et de réanimation (Sfar) Société de réanimation de langue française (SRLF), Laterre PF, Misset B; Société de pathologie infectieuse de langue française (SPILF), Bru JP, Gauzit R, Sotto A; Association française de chirurgie (AFC), Brigand C, Hamy A; Société française de chirurgie digestive (SFCD), Tuech JJ, (2015) Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med 34: 117–130 [CrossRef] [PubMed] [Google Scholar]
  • Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O’Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG, (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50: 133–164 [CrossRef] [PubMed] [Google Scholar]
  • Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TMJr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL, (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis 63: 575–582 [CrossRef] [PubMed] [Google Scholar]
  • De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M, (2014) High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 18: R90 [CrossRef] [PubMed] [Google Scholar]
  • Akova M, Daikos GL, Tzouvelekis L, Carmeli Y, (2012) Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 18: 439–448 [PubMed] [Google Scholar]
  • Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL, (2012) Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25: 682–707 [PubMed] [Google Scholar]
  • Daikos GL, Tsaousi, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A, (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58: 2322–2328 [CrossRef] [PubMed] [Google Scholar]
  • Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A, Farcomeni A, Morelli A, Venditti M, (2016) Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect 22: 444–450 [PubMed] [Google Scholar]
  • Bassetti M, Peghin M, Pecori D, (2016) The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis 29: 583–594 [CrossRef] [PubMed] [Google Scholar]
  • www.cnr-resistance-antibiotiques.fr/ressources/pages/Rapport_CNR_2014.pdf [Google Scholar]
  • http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf [Google Scholar]
  • http://ecdc.europa.eu/en/publications/Publications/8-Dec-2016-RRA-Acinetobacter%20baumannii-Europe.pdf [Google Scholar]
  • Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC, (2015) Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: A multicenter prospective observational study. Crit Care Med 43: 1194–1204 [CrossRef] [PubMed] [Google Scholar]
  • Gergely Szabo B, Kadar B, Szidonia Lenart K, Dezsenyi B, Kunovszki P, Fried K, Kamotsay K, Nikolova R, Prinz G, (2016) Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect 22: 990–995 [PubMed] [Google Scholar]
  • Di Bella S, Nisii C, Petrosillo N, (2015) Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature. Int J Antimicrob Agents 46: 8–12 [CrossRef] [PubMed] [Google Scholar]
  • Aldape MJ, Heeney DD, Bryant AE, Stevens DL, (2015) Tigecycline suppresses toxin. A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother 70: 153–159 [PubMed] [Google Scholar]
  • Debast SB, Bauer MP, Kuijper EJ, (2014) European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20: 1–26 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.